Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 12/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6652651 | 0.81 | KDM1A (0.50) | KDM1AKMT2ANPSR1 | |
| SCHEMBL9755333 | 0.79 | KDM1A (0.51) | KDM1AKMT2AMEN1 | |
| SCHEMBL9755390 | 0.78 | TOP2A (0.55) | KDM1AKMT2AMEN1 | |
| SCHEMBL9755413 | 0.76 | TOP2A (0.50) | KDM1AKMT2AMEN1 | |
| SCHEMBL28165939 | 0.76 | KDM1A (0.50) | KDM1AKMT2AMEN1 | |
| SCHEMBL30164507 | 0.76 | ALDH1A1 (0.52) | KDM1AACHEKMT2A | |
| SCHEMBL2773901 | 0.76 | ALDH1A1 (0.52) | KDM1AACHEKMT2A | |
| Acridine SCHEMBL29278305 | 0.75 | ALDH1A1 (0.68) | KDM1AACHEKMT2ANPSR1MEN1 | |
| SCHEMBL29033070 | 0.75 | ALDH1A1 (0.50) | KDM1AACHEKMT2A | |
| Bromide SCHEMBL17508351 | 0.75 | ALDH1A1 (0.50) | KDM1AACHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 975 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011528275-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2313122-A1 | DRUG DELIVERY MEDICAL DEVICE | Micell Technologies, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010009335-A1 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
| EP-1919929-A4 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1919929-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | claimed |
| WO-2007019221-A2 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | RND PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | claimed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | claimed |
| US-20260014172-A1 | ABIRATERONE PRODRUGS | ASTELLAS US LLC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250186463-A1 | ABIRATERONE DECANOATE PRODRUGS AND USE IN THERAPY | ASTELLAS US LLC | 2025-06-12 | — | — | US | disclosed |
| CN-119735613-A | Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine | 武田药品工业株式会社 | 2025-04-01 | — | — | CN | disclosed |
| WO-1998047890-A1 | SUBSTITUTED BENZOPYRAN DERIVATIVES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1998-10-29 | — | — | WO | disclosed |
| WO-1998016227-A9 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | — | 1998-07-30 | — | — | WO | disclosed |
| WO-1998022101-A2 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS AS ANTI-ANGIOGENIC AGENTS | G.D. SEARLE & CO. (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998016227-A1 | METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA | G.D. SEARLE & CO. (US) | 1998-04-23 | — | — | WO | disclosed |
| EP-0393575-B1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | SEARLE & CO (US) | 1994-03-16 | — | — | EP | disclosed |
| EP-0393575-A1 | Neoplasia treatment compositions containing antineoplastic agent and side-effect reducing protective agent | G.D. Searle & Co. (US) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014172-A1 | ABIRATERONE PRODRUGS | SHBG, CYP17A1, HSD17B11 | KDM1A 4293/4885ACHE 4126/4885KMT2A 4385/4885 |
| US-20250186463-A1 | ABIRATERONE DECANOATE PRODRUGS AND USE IN THERAPY | AR, CYP21A2, CYP17A1 | KDM1A 2874/4885ACHE 4772/4885KMT2A 3244/4885 |
| US-20090054369-A1 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS | SI, SLC29A2, SLC29A1 | KDM1A 3524/4885ACHE 631/4885KMT2A 2193/4885 |
| US-12440494-B2 | Compounds useful for inhibiting RAF dimers | BRAF, RAF1, NRAS | KDM1A 3882/4885ACHE 4725/4885KMT2A 2985/4885 |
| US-20250361232-A1 | SUBSTITUTED ACETYLENIC PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS KINASE INHIBITORS | MAP4K2, MAP3K19, MAP3K1 | KDM1A 870/4885ACHE 1906/4885KMT2A 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.